Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

791 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Among authors: phillips ka. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis.
Alexander M, Jachno K, Phillips KA, Seymour JF, Slavin MA, Cheung A, Shen V, Maarouf D, Wolfe R, Lingaratnam S. Alexander M, et al. Among authors: phillips ka. J Oncol Pharm Pract. 2023 Jun 16:10781552231180875. doi: 10.1177/10781552231180875. Online ahead of print. J Oncol Pharm Pract. 2023. PMID: 37322897
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement.
Cui W, Rocconi RP, Thota R, Anderson RA, Bruinooge SS, Comstock IA, Denduluri N, Gassman A, Gralow J, Hutt KJ, Amiri-Kordestani L, Lambertini M, Leighton J, Lu KH, Mostoufi-Moab S, Pollastro T, Pradhan S, Saber H, Schenkel C, Spratt D, Wedam S, Phillips KA. Cui W, et al. Among authors: phillips ka. Lancet Oncol. 2023 Oct;24(10):e415-e423. doi: 10.1016/S1470-2045(23)00390-X. Lancet Oncol. 2023. PMID: 37797647 Review.
The Lancet Breast Cancer Commission.
Coles CE, Earl H, Anderson BO, Barrios CH, Bienz M, Bliss JM, Cameron DA, Cardoso F, Cui W, Francis PA, Jagsi R, Knaul FM, McIntosh SA, Phillips KA, Radbruch L, Thompson MK, André F, Abraham JE, Bhattacharya IS, Franzoi MA, Drewett L, Fulton A, Kazmi F, Inbah Rajah D, Mutebi M, Ng D, Ng S, Olopade OI, Rosa WE, Rubasingham J, Spence D, Stobart H, Vargas Enciso V, Vaz-Luis I, Villarreal-Garza C; Lancet Breast Cancer Commission. Coles CE, et al. Among authors: phillips ka. Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747-5. Online ahead of print. Lancet. 2024. PMID: 38636533 Review. No abstract available.
Suspect Screening Analysis of Pooled Human Serum Samples Using GC × GC/TOF-MS.
Phillips KA, Chao A, Church RL, Favela K, Garantziotis S, Isaacs KK, Meyer B, Rice A, Sayre R, Wetmore BA, Yau A, Wambaugh JF. Phillips KA, et al. Environ Sci Technol. 2024 Jan 30;58(4):1802-1812. doi: 10.1021/acs.est.3c05092. Epub 2024 Jan 13. Environ Sci Technol. 2024. PMID: 38217501
791 results